Table 4.
Subgroup analyses and testing for interaction
| MV-adjusted RHa (95% CI) per unit increase in TSH |
||||
|---|---|---|---|---|
| All death | P for interaction | CV death | P for interaction | |
| Age | ||||
| <73 yr | 0.93 (0.80–1.08) | 0.04 | 1.15 (0.94–1.41) | 0.59 |
| ≥73 yr | 1.04 (0.98–1.10) | 1.05 (0.95–1.17) | ||
| Prevalent CHD | ||||
| No (n = 1215) | 0.96 (0.90–1.04) | 0.15 | 0.98 (0.85–1.12) | 0.29 |
| Yes (n = 372) | 1.09 (0.99–1.20) | 1.15 (1.00–1.32) | ||
| Thyroid hormone use | ||||
| No (n = 1467) | 0.97 (0.90–1.04) | 0.02 | 1.03 (0.93–1.14) | 0.16 |
| Yes(n = 120) | 1.07 (0.99–1.18) | 1.28 (0.93–1.77) | ||
a
Adjusted for age, race, smoking status, clinic site, history of non-skin cancer, and self-reported health status. Models including thyroid hormone users also adjusted for thyroid hormone use.